Beryl Drugs Ltd Stock Analysis

BSE: 524606 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 06-Feb-2023 18:01
12.64 -0.66 (-4.96%)

DeciZen - Make an Informed Decision on Beryl Drugs

M-Cap below 100cr DeciZen not available

Beryl Drugs Price Chart

P/E Ratio ( SA) :
Market Cap :
6.4 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Beryl Drugs Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Beryl Drugs Ltd is a below average quality company.

2. Is Beryl Drugs Ltd undervalued or overvalued?

The key valuation ratios of Beryl Drugs Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Beryl Drugs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Beryl Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Beryl Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Beryl Drugs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 7%5.3%3.2%2.9%3%9.2%7.4%2.3%1.9%-2.6%-
Value Creation Index -0.5-0.6-0.8-0.8-0.8-0.3-0.5-0.8-0.9-1.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 14.614.613.313.11115.11312.814.114.619
YoY Gr. Rt. %--0.1%-9.1%-1.4%-16.2%37.8%-14.4%-1.1%9.9%3.6%-
YoY Gr. Rt. %--28.8%-71.2%20%16.7%528.6%-10.6%-92.4%-266.7%NA-
BVPS (₹) 12.112.612.813.113.413.114.81515.614.315.4
Adj Net Profit
Cash Flow from Ops. 0.8-0.30.7-0.10.3-
Debt/CF from Ops. 1.1-4.82.5-13.56.3-14.8128.315.1-18.5-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -0%5.9%4.1%3.6%
Adj EPS -206.5%-243.8%-203%NA
BVPS 1.91.4-1.1-8
Share Price -8.4% -2.3% 39.5% -9.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity %
Op. Profit Mgn %
Net Profit Mgn %
Debt to Equity
Working Cap Days 109124165170215185195186232273132
Cash Conv. Cycle 38498010414911495729312535

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.73

Sales growth is good in last 4 quarters at 37.20%

Return on Equity is Poor

Sales growth has been subdued in last 3 years 4.05%

Latest Financials - Beryl Drugs Ltd.

Standalone Consolidated
TTM EPS (₹) -0 -
TTM Sales (₹ Cr.) 19.3 -
BVPS (₹.) 15.4 -
Reserves (₹ Cr.) 3 -
P/BV 0.82 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 7.50 / 18.00
All Time Low / High (₹) 0.60 / 53.00
Market Cap (₹ Cr.) 6.4
Equity (₹ Cr.) 5.1
Face Value (₹) 10
Industry PE 36.3

Management X-Ray of Beryl Drugs :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Beryl Drugs

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Beryl Drugs Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Beryl Drugs on 06-Feb-2023 18:01 is : 12.64.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 06-Feb-2023 18:01 the market cap of Beryl Drugs stood at ₹ 6.41.
The latest PE ratio of Beryl Drugs as of 06-Feb-2023 18:01 is 0.00.
The latest PB ratio of Beryl Drugs as of 06-Feb-2023 18:01 is 0.82
The 52-week high of Beryl Drugs is ₹ 18.00 and the 52-week low is ₹ 7.50.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Beryl Drugs is ₹ 19.27 ( Cr.) .

About Beryl Drugs Ltd

Beryl Drugs incorporated in 1993 is into manufacturing and marketing of branded, generic pharmaceutical formulations. The company is one of leading manufacturer of I.V.fluids and small volume injectables.

Beryl has emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products. 

The manufacturing facilities of the company are in compliance with WHO GMP specifications.

Company owns brands like BERI-CEF injection, F-Neuron, Amplicillin INJ, P-Mol, Biprox, B-Flox and many more.

The shares of Beryl Drugs are listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange.

Products manufactured by the company:

  • Small volume injectables in liquid form
  • Small volume injectables in dry powder form
  • Variety of eye and ear drops
  • I.V.Fluids in polypack and glass bottles
  • Variety of vetrinary medicines


The company has received ISO 9001:2000 certification for its quality management.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now